- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01547312
Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)
October 13, 2015 updated by: Merck Sharp & Dohme LLC
A Randomized Clinical Trial Using Fine Needle Aspiration For Evaluation of Hepatic Pharmacokinetics of MK-5172 in Participants With Chronic Hepatitis C
This study is divided into 2 segments, and proposes to qualify fine needle aspiration (FNA) as a platform to evaluate the hepatic pharmacokinetics of low and high oral doses of Grazoprevir (MK-5172) in non-cirrhotic participants chronically infected with hepatitis C virus (HCV).
The first segment, is a procedural pilot conducted prior to the main study, that is aimed at ensuring optimal execution of the FNA procedure.
During the procedural pilot, core needle biopsy (CNB) will be performed on participants as part of their standard of care, but no study drugs will be administered, nor will any procedures other than FNA be conducted.
The second segment, the main study, is designed to evaluate the feasibility of measuring Grazoprevir by FNA.
During the main study, drugs will be administered, and other additional procedures will be conducted.
Study Overview
Status
Withdrawn
Conditions
Study Type
Interventional
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Has chronic compensated HCV infection.
- No contraindications to CNB or FNA procedures.
- Pilot study only: All comers with chronic HCV already scheduled to undergo CNB for fibrosis staging.
- Pilot study only: Requires a diagnostic liver biopsy to monitor progression of liver disease.
- Pilot study only: Does not have cirrhosis.
- Main study only: Males or non-pregnant and postmenopausal females willing to use medically acceptable contraception during, and for 6 months or longer after study.
- Main study only: Body mass index of 18.5 - 32.0 kg/m^2.
- Main study only: Can avoid aspirin, anticoagulants, and non steroidal inflammatory agents.
- Main study only: Has undergone prior treatment or is treatment naive for chronic HCV infection.
Exclusion Criteria for Main study only:
- History of any of the following: stroke, chronic seizures, major neurological disorders, gastric bypass surgery or bowel resection.
- No viral response to prior interferon based therapy.
- Prior treatment for HCV with an NS3/4A protease inhibitor.
- History of either clinically significant, uncontrolled endocrine, gastrointestinal, cardiovascular, hematological, immunological, renal, respiratory, or genitourinary abnormalities/diseases.
- History of neoplastic or myeloproliferative disease.
- Has any of the following : cirrhosis, decompensated liver disease, or other advanced liver disease, hepatocellular carcinoma, infection with human immunodeficiency virus (HIV), or hepatitis B.
- Evidence of high grade bridging fibrosis from prior liver biopsy or chronic hepatitis not caused by HCV.
- History of illicit drug use or alcohol abuse.
- Had surgery, donated at least one unit of blood, or participated in any other investigational study within 4 weeks prior to screening visit.
- History of multiple and/or severe allergies.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Main Pt. 2: 800 mg Grazoprevir + Peg-IFN/RBV
800 mg Grazoprevir combined with Peg-Interferon/Ribavirin treatment.
|
Polyethyleneglycolated Interferon alfa-2b at 1.5 ug/kg/week, administered subcutaneously, once a week, over the entire course of the study.
Other Names:
Tissue samples are collected at 3 separate visits, with each collection consisting of 3-4 fine needle aspiration (FNA) passes through the liver, guided by ultrasound.
Tissue samples are collected at 1 of six possible visits by core needle biopsy (CNB) of the liver.
Blood is collected from multiple blood draws, with the total volume for each participant not expected to exceed 500 ml.
Ribavirin, 600-1400 mg administered orally, twice daily, over the entire course of the study.
Other Names:
800 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
|
Experimental: Main Pt. 2: 100 mg Grazoprevir + Peg-IFN/RBV
100 mg Grazoprevir combined with Peg-Interferon/Ribavirin treatment.
|
Polyethyleneglycolated Interferon alfa-2b at 1.5 ug/kg/week, administered subcutaneously, once a week, over the entire course of the study.
Other Names:
Tissue samples are collected at 3 separate visits, with each collection consisting of 3-4 fine needle aspiration (FNA) passes through the liver, guided by ultrasound.
Tissue samples are collected at 1 of six possible visits by core needle biopsy (CNB) of the liver.
Blood is collected from multiple blood draws, with the total volume for each participant not expected to exceed 500 ml.
Ribavirin, 600-1400 mg administered orally, twice daily, over the entire course of the study.
Other Names:
100 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
|
Experimental: Main Pt.1: 800 mg Grazoprevir
800 mg Grazoprevir.
|
Tissue samples are collected at 3 separate visits, with each collection consisting of 3-4 fine needle aspiration (FNA) passes through the liver, guided by ultrasound.
Tissue samples are collected at 1 of six possible visits by core needle biopsy (CNB) of the liver.
Blood is collected from multiple blood draws, with the total volume for each participant not expected to exceed 500 ml.
800 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
|
Experimental: Procedural Pilot
Optimization of FNA procedure.
|
Tissue samples from the liver are collected by CNB as part of standard of care, and also by FNA during a single visit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants from whom detectable concentrations of hepatic Grazoprevir are obtained by FNA.
Time Frame: Days 7-12.
|
Days 7-12.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2012
Primary Completion (Anticipated)
November 1, 2012
Study Completion (Anticipated)
November 1, 2012
Study Registration Dates
First Submitted
February 2, 2012
First Submitted That Met QC Criteria
March 2, 2012
First Posted (Estimate)
March 7, 2012
Study Record Updates
Last Update Posted (Estimate)
October 14, 2015
Last Update Submitted That Met QC Criteria
October 13, 2015
Last Verified
October 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis, Chronic
- Hepatitis C, Chronic
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Antimetabolites
- Antineoplastic Agents
- Hematinics
- Interferons
- Ribavirin
- Liver Extracts
- Grazoprevir
Other Study ID Numbers
- 5172-022
- 2011-004978-29 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hepatitis C
-
Sohag UniversityRecruiting
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
Humanity and Health Research CentreBeijing 302 Hospital; Nanfang Hospital of Southern Medical University; Yamanashi...Recruiting
-
Hospices Civils de LyonCompleted
-
Sunshine Lake Pharma Co., Ltd.CompletedChronic Hepatitis cChina
-
Ascletis Pharmaceuticals Co., Ltd.CompletedChronic Hepatitis cChina
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
Clinical Trials on Peg-Interferon
-
Kaohsiung Medical University Chung-Ho Memorial...Completed
-
NovartisHuman Genome Sciences Inc.CompletedChronic Hepatitis CTaiwan, Germany, Greece, Italy, Spain, United Kingdom, France, Canada, Australia, India, Poland, Thailand
-
Brooke Army Medical CenterT.R.U.E. Research FoundationCompleted
-
French National Agency for Research on AIDS and...Merck Sharp & Dohme LLCCompletedHCV Infection | Liver Cirrhosis, ExperimentalFrance
-
Pusan National University HospitalUnknownChronic Hepatitis BKorea, Republic of
-
M.D. Anderson Cancer CenterNovartisCompletedLeukemia, Myeloid, ChronicUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedOvarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity CancerUnited States
-
Shanghai General Hospital, Shanghai Jiao Tong University...CompletedRecurrence | Hematological NeoplasmsChina
-
M.D. Anderson Cancer CenterSchering-PloughTerminatedLeukemia, Myeloid, Philadelphia-PositiveUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)TerminatedLymphomaUnited States